Selling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insiders

Simply Wall St.07-28

While Genscript Biotech Corporation (HKG:1548) shareholders have enjoyed a good week with stock up 20%, they need remain vigilant. Although prices were relatively low, insiders chose to sell US$5.8m ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2654625020?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-07-28 09:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2654625020","market":"us","top_or_hot":-1,"title":"Selling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insiders","media":"Simply Wall St.","content":"<div>\n<p>While Genscript Biotech Corporation (HKG:1548) shareholders have enjoyed a good week with stock up 20%, they need remain vigilant.  Although prices were relatively low, insiders chose to sell US$5.8m ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/selling-us58m-of-stock-was-lucrative-decision-for-genscript\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Selling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insiders</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSelling US$5.8m Of Stock Was Lucrative Decision For Genscript Biotech Insiders\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-28 09:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/selling-us58m-of-stock-was-lucrative-decision-for-genscript><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>While Genscript Biotech Corporation (HKG:1548) shareholders have enjoyed a good week with stock up 20%, they need remain vigilant.  Although prices were relatively low, insiders chose to sell US$5.8m ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/selling-us58m-of-stock-was-lucrative-decision-for-genscript\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1141","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/selling-us58m-of-stock-was-lucrative-decision-for-genscript","article_id":"2654625020","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1548/genscript-biotech-shares/news/selling-us58m-of-stock-was-lucrative-decision-for-genscript","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2654625020","pubTimestamp":1785202148,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"While Genscript Biotech Corporation ( HKG:1548 ) shareholders have enjoyed a good week with stock up 20%, they need...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK1576":"医药外包概念","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC","01548":"金斯瑞生物科技","BK4588":"碎股","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK4585":"ETF&股票定投概念","HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","BK4581":"高盛持仓","XBI":"SPDR S&P Biotech ETF"},"translate_title":"对于金斯瑞生物技术内部人士来说，出售 580 万美元的股票是一个有利可图的决定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XBI":1.5,"01548":1},"content_text":"While Genscript Biotech Corporation (HKG:1548) shareholders have enjoyed a good week with stock up 20%, they need remain vigilant.  Although prices were relatively low, insiders chose to sell US$5.8m worth of stock in the past 12 months. This could be a sign of impending weakness.      While insider transactions are not the most important thing when it comes to long-term investing,  we do think it is perfectly logical to keep tabs on what insiders are doing.  We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.Advertisement The Last 12 Months Of Insider Transactions At Genscript Biotech   The CEO & COO, Weihui Shao, made the biggest insider sale in the last 12 months. That single transaction was for HK$3.8m worth of shares at a price of HK$12.12 each.    That means that even when the share price was below the current price of HK$16.82, an insider wanted to cash in some shares.  As a general rule we consider it to be discouraging when insiders are selling below the current price, because it suggests they were happy with a lower valuation.  However, while insider selling is sometimes discouraging, it's only a weak signal.   This single sale was just 17% of Weihui Shao's stake.       Genscript Biotech insiders didn't buy any shares over the last year.    The chart below shows insider transactions (by companies and individuals) over the last year.  If you want to know exactly who sold, for how much, and when, simply click on the graph below!  View our latest analysis for Genscript Biotech SEHK:1548 Insider Trading Volume July 28th 2026 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. (Hint: Most of them are flying under the radar).   Insiders At Genscript Biotech Have Sold Stock Recently   Over the last three months, we've seen significant insider selling at Genscript Biotech.  In total,  insiders  sold HK$3.8m worth of shares in that time, and we didn't record any purchases whatsoever.  In light of this it's hard to argue that all the insiders think that the shares are a bargain.     Insider Ownership  Many investors like to check how much of a company is owned by insiders.  A high insider ownership often makes company leadership more mindful of shareholder interests.   From our data, it seems that Genscript Biotech insiders own 0.2% of the company, worth about HK$77m.   We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure.   Overall, this level of ownership isn't that impressive, but it's certainly better than nothing!   So What Does This Data Suggest About Genscript Biotech Insiders?  Insiders haven't  bought Genscript Biotech stock in the last three months, but there was some selling.     And there weren't any purchases to give us comfort, over the last year.    Insider ownership isn't particularly high, so this analysis makes us cautious about the company.  We'd practice some caution before buying!      So while it's helpful to know what insiders are doing in terms of buying or selling, it's also helpful to know the risks that a particular company is facing.    Case in point: We've spotted 2 warning signs for Genscript Biotech you should be aware of.    Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies. For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654625020","isCrawlerRequest":true}